Australia Refuses To Reimburse Gilead's Sovaldi
This article was originally published in PharmAsia News
Executive Summary
Australian authorities have decided not to reimburse Sovaldi, Gilead's $84,000 treatment for hepatitis C that is being made available in many developing countries for about 1% of that price.